Silver Book

Silver Book Fact

Aspirin, beta-blockers, angiotensin-converting enzyme inhibitors, and statins, when taken in combination, have been estimated to reduce the relative risk of coronary heart disease mortality by 80%, compared with a placebo.

Choudhry N, Avorn J, Antman E, Schneeweiss S, et al. Should Patients Receive Secondary Prevention Medications For Free After A Myocardial Infarction? An economic analysis. Health Affairs. 2007; 26(1): 186-194. https://www.healthaffairs.org/doi/abs/10.1377/hlthaff.26.1.186?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed

Reference

Title
Should Patients Receive Secondary Prevention Medications For Free After A Myocardial Infarction? An economic analysis
Publication
Health Affairs
Publisher
Project HOPE
Publication Date
2007
Authors
Choudhry N, Avorn J, Antman E, Schneeweiss S, et al.
Volume & Issue
Volume 26, Issue 1
Pages
186-194
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Atrial fibrillation ablation prevents recurrence of AFib
    Atrial fibrillation ablation, which involves using a catheter inserted into the heart to destroy electrical conduction tissue in or near the atria, prevents the recurrence of atrial fibrillation in up…  
  • TAVR v. SAVR in Intermediate-Risk SAS Patients
    At 1-year, severe aortic stenosis (SAS) patients with intermediate surgical mortality risk who underwent transcatheter aortic valve replacement (TAVR), had all-cause mortality rates of 7.4% (compared to 13% for surgical…  
  • Effectiveness of treating ischemic strokert-PA within 3 hours of symptom onset
    A study of the  victims with effectiveness of treating ischemic strokert-PA within 3 hours of symptom onset showed a decrease in rehabilitation costs of $1.4 million and nursing home costs of…  
  • Effect of optimal anticoagulation
    If 50% of atrial fibrillation patients who currently receive warfarin in routine medical care were optimally anticoagulated, 9,852 emboli would be prevented and $1.3 billion would be saved each year.  
  • Medicines in Development for Heart Disease and Stroke, 2008